PRMT1 and frontotemporal dementia: Inhibiting PRMT1 activity, for instance through the use of the inhibitor MS023, can mitigate polyGR/polyPR‐induced neuronal toxicity, enhance neuronal survival, and preserve axonal integrity, indicating that PRMT1 exerts a pathogenic influence in C9orf72‐related ALS/FTD [181].